Omega-3 fatty acids and heart failure
Related Experiment Video
Updated: Jun 19, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Roberto Marchioli1, Maria Giuseppina Silletta, Giacomo Levantesi
1Consorzio Mario Negri Sud, Via Nazionale, Santa Maria Imbaro, Italy. marchioli@negrisud.it
Abstract:
During the past three decades, the protective role of omega (n)-3 polyunsaturated fatty acids (PUFA), mainly eicosapentaenoic acid and docosahexaenoic acid, in patients with coronary heart disease has been widely reported. The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure (GISSI-HF) study, a large-scale clinical trial, recently showed that n-3 PUFA (850-882 mg/d) reduced mortality and admission to the hospital for cardiovascular reasons in patients with chronic heart failure (HF) who were already receiving recommended therapies. The favorable effects of n-3 PUFA in GISSI-HF suggest that marine fish oils could confer protection in HF mainly through their antiarrhythmic action and in part by influencing the mechanisms related to HF progression. This article reviews recent clinical and experimental evidence on the effect of n-3 PUFA in coronary heart disease, with particular attention on HF and its pathophysiologic mechanisms.
Related Concept Videos
Heart Failure III: Clinical Manifestations
Heart Failure I: Introduction
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure II: Pathophysiology
Structure of Lipids